'Best Results' Yet for Poor-Prognosis Elderly With DLBCLThe Oncology ReportSAN DIEGO – Stretching out the delivery of rituximab significantly improved overall and event-free survival among older patients with poor-prognosis diffuse large B-ce…
High-dose chemotherapy, autologous stem cell transplantation failed to improve …HemOncTodayPatients received rituximab (Rituxan; Genentech, Idec Pharmaceuticals) in both arms during induction treatment in two of the trials. Median follow-up was up to…
MedIndiaOverall Survival in Follicular Lymphoma Patients Not Improved by Autologous …MedIndiaIn an accompanying editorial, Caron A. Jacobson and Dan L. Longo, MD, at the Department of Medicine at Brigham and Women's Hospital in Boston, write that…
Renewed Interest in Ibritumomab for Non-Hodgkin's LymphomaMedscapeBefore the new FDA ruling, the bioscan protocol required patients to receive an infusion of rituximab on day 1, which was followed by a diagnostic dose of radiolabeled indium-111 [ib…
Rituxan Prolongs HIV-Related Lymphoma SurvivalAIDSmeds.com HIV/AIDS Treatment NewsFor people diagnosed with AIDS-related lymphomas, adding Rituxan (rituximab) to standard chemotherapy has a major positive effect on survival, according to new German coh…
Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE(R) in …MarketWatch (press release)Also presented were biomarker data from a phase 3 study comparing VELCADE(R) (bortezomib) and rituximab (VcR) to rituximab (R) alone in patient…
ASH: Rituximab Leads Way in Older Mantle Cell PatientsMedPage TodayAn induction regimen based on rituximab (Rituxan), followed by rituximab maintenance, now appears to be the best treatment choice for older patients with mantle cell lymphoma. Among tho…
ASH: Two Immunochemotherapy Regimens With Rituximab for Newly Diagnosed …Cancer NetworkThe 554 patients enrolled had bulky FL—stage II and higher, and had not received any prior treatment—and were randomized to either the CHOP-R arm, CHOP chemoth…
Less Is More for Rituximab in Low-Burden Follicular LymphomaMedscapeDecember 14, 2011 — For patients with low-tumor-burden follicular lymphoma, new data suggest that treatment with rituximab (Rituxan, Genentech) is better than a "watch-and-wait&…
Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses … – CNBCSan Francisco Luxury NewsThe combination of REVLIMID (lenalidomide) and rituximab, also referred to as the R-squared (or R(2)) regimen pioneered by Nathan Fowler, MD and col…